NCI R50 Clinician Scientist Award

NCI R50 临床科学家奖

• 批准号: 10569255
• 负责人: Brian A. Jonas
• 金额: $ 8.67万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10569255
• 关键词: Acute Lymphocytic Leukemia; Acute leukemia; American College of Radiology Imaging Network; Award; Biological Markers; California; Cancer Therapy Evaluation Program; Clinical; Clinical Research; Clinical Treatment; Clinical Trials; Clinical Trials Network; Clinical Trials Unit; Complement; Comprehensive Cancer Center; Data; Dedications; Detection; Development; Disease; Doctor of Philosophy; Dysmyelopoietic Syndromes; Eastern Cooperative Oncology Group; Educational process of instructing; Growth; Hematologic Neoplasms; Hematology; Heme; Individual; Institution; Investigational Therapies; Leadership; Malignant Neoplasms; Monitor; National Clinical Trials Network; Oncology; Oncology Group; Participant; Patients; Prevention; Productivity; Qualifying; Research; Safety; Scientist; Services; Shapes; Southwest Oncology Group; Specialist; Therapeutic; Time; Training; cancer care; cancer clinical trial; cancer therapy; clinical trial implementation; design; improved; leukemia; leukemic stem cell; member; mid-career faculty; multidisciplinary; novel; programs; therapeutic target; translational study; working group

ABSTRACT/SUMMARY NCI clinical trials networks are essential to strengthen the cancer care of the nation by expediting the discovery of novel cancer treatments and therapeutic strategies. Central to this effort are the clinician scientists who development, implement, manage, and provide oversight to these individual trials and trial networks. While essential, these clinicians are frequently tasked with significant clinical, administrative, and teaching responsibilities that may inhibit substantiative contribution to NCI-sponsored clinical trial activity. The R50 Research Specialist /Clinician Scientist Award is designed to protect time and allow the clinician scientist to significantly contribute to NCI-sponsored clinical trials and NCI clinical trials networks through leadership in the development of national clinical trials, implementation of NCI clinical trials in their institutions, and national service to the NCI clinical trials networks. Dr. Brian Jonas, MD, PhD, is a leukemia specialist and an Associate Professor within the Department of Hematology/Oncology at UC Davis Comprehensive Cancer Center (UCDCCC). As an active and highly dedicated clinical scientist and trialist at UC Davis, he has established himself as a leader in opening clinical trials for the treatment of AML, MDS, acute lymphoblastic leukemia (ALL) and other hematologic malignancies. Moreover, he has received the coveted “Top Accrurer” Award within the cancer clinical trials unit. His clinical research is complemented by his translational studies involving AML biomarkers, chemosensitivity and therapeutic targeting of leukemia stem cells. As an asset to UCDCCC, he has served as PI on several clinical trials and as a leader in clinical trials management. This includes chairing the UCDCCC Hematologic Malignancies Disease Team Committee and the UCDCCC Data and Safety Monitoring Committee. In addition to his contributions at UC Davis, Dr. Jonas has contributed to multidisciplinary clinical and translational teams such as the Leukemia Committee and Working Group for the Southwest Oncology Group (SWOG), and the Calif ornia Cancer Consortium to shape and inf orm clinical trial portf olios at the UCDCCC, the National Clinical Trials Network (NCTN) and the Experimental Therapeutics Clinical Trials Network (ET-CTN). This includes his service as national chair of two ECTCN trials developed through the CTEP Project Team mechanism and the SWOG champion for an ECOG-ACRIN AML trial in development through the NCTN. He is also an active participant in the UM1 Consortium, the California Cancer Consortium (CCC), and a member of the CCC Heme Working Group. Overall, Dr. Jonas is a well-qualified clinician scientist candidate for the NCI R50 Research Specialist Award and has demonstrated prior and continuing leadership in the development of national clinical trials, implementation of NCI-sponsored clinical trials at UCD, and service to NCI clinical trial networks through participation in our CCC. The R50 award will facilitate continued growth of his research program and advancement of his institutional and national leadership.

摘要/摘要 NCI临床试验网络对于通过发现加快发现来加强国家的癌症护理至关重要 新型的癌症治疗和治疗策略。这项工作的核心是临床科学家 开发，实施，管理和提供这些个人试验和试验网络的监督。尽管 至关重要的是，这些临床医生经常承担重要的临床，行政和教学的任务 可能抑制对NCI赞助的临床试验活动的实质性贡献的责任。 R50 研究专家 /临床医生奖旨在保护时间并允许临床科学家 通过领导才能在 开发国家临床试验，在其机构中实施NCI临床试验以及国家 为NCI临床试验网络提供服务。 医学博士Brian Jonas博士是白血病专家，也是该系的副教授 加州大学戴维斯分校综合癌症中心（UCDCCC）的血液学/肿瘤学。作为一个活跃而高度的 他在加州大学戴维斯分校的敬业临床科学家和审判员，他已成为开放临床领域的领导者 治疗AML，MDS，急性淋巴细胞性白血病（ALL）和其他血液学恶性肿瘤的试验。 此外，他在癌症临床试验部门获得了令人垂涎的“顶级宣传员”奖。他的临床 研究是由他的翻译研究完成的，涉及AML生物标志物，化学敏感性和 白血病干细胞的治疗靶向。作为UCDCCC的资产，他曾在几个临床上担任PI 试验和临床试验管理的领导者。这包括主持UCDCCC血液学 恶性病小组委员会和UCDCCC数据和安全监测委员会。 除了在加州大学戴维斯分校的贡献外，乔纳斯博士还为多学科临床和翻译做出了贡献 西南肿瘤学集团（SWOG）等白血病委员会和工作组等团队 加利福尼亚Ornia Cancer Cansortium在UCDCCC（国家临床 试验网络（NCTN）和实验治疗临床试验网络（ET-CTN）。这包括他 作为通过CTEP项目团队机制开发的两项ECTCN试验的国家主席的服务 通过NCTN进行了ECOG-AML AML试验的Swog Champion。他也是一个活跃的 参加UM1财团，加利福尼亚癌症联盟（CCC）和CCC血红素成员的参与者 工作组。总体而言，乔纳斯博士是NCI R50研究的合格临床科学家候选人 专家奖，并在国家临床发展方面表现出了先前和持续的领导 试验，在UCD实施NCI赞助的临床试验，以及通过NCI临床试验网络的服务 参与我们的CCC。 R50奖将有助于他的研究计划的持续增长和 他的机构和国家领导力的进步。